SNNA Sienna Biopharmaceuticals Inc.

Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference

Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference

WESTLAKE VILLAGE, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to participate in a fireside chat at the BMO Capital Markets Prescriptions for Success Healthcare Conference, Wednesday, Dec. 12, 2018, 10:20 a.m. Eastern Time, in New York.

The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at . An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop a unique, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.

For more information, visit the Company’s website at .

Contact:

Investors

Sean Andrews



818-629-2244

Media

Caroline Van Hove



818-575-6250

Crystal Muilenburg



818-584-1035

EN
06/12/2018

Underlying

SNNASienna Biopharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sienna Biopharmaceuticals Inc.

 PRESS RELEASE
Free
SNNA Sienna Biopharm...

Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Biddi...

Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures Bids due on December 2, 2019 by 5:00 p.m. Eastern Time WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order approving Sienna’s proposed bidding procedures and Chapter 11 sale process timeline (the “Bidding Procedures Order”).1 Under the Bidding Procedures...

November 14, 2019 1 EN
 PRESS RELEASE
Free
SNNA Sienna Biopharm...

Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delist...

Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice -- Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 12, 2019, the Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for continued listing on the Nasdaq Stock Market (“Nasdaq”), subject to certain conditions, including the following: On or be...

November 14, 2019 1 EN
 PRESS RELEASE
Free
SNNA Sienna Biopharm...

Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001...

Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair WESTLAKE VILLAGE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a Premarket Notification 510(k) submission to  the U.S. Food and Drug Administration (FDA) for SNA-001, a topical pre-treatment to standard laser devices to remove unwanted light hair, and has received acknowledgement from FDA that the submission has been accepted. ...

October 7, 2019 1 EN
 PRESS RELEASE
Free
SNNA Sienna Biopharm...

Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Pr...

Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code. “We believe this decision is in the best interests of Sienna and its stakeholders,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “The protections afforded by Chapter 11 provide for ...

September 17, 2019 1 EN
 PRESS RELEASE
Free
SNNA Sienna Biopharm...

Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strat...

Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strategic Alternatives WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives to maximize shareholder value. With Cowen's assistance, Sienna will continue to explore capital raising to enable the initiation of its planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib), in...

August 5, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch